These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24117597)

  • 21. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
    Seino Y; Yabe D; Takami A; Niemoeller E; Takagi H
    J Diabetes Complications; 2015; 29(8):1304-9. PubMed ID: 26342556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
    Nauck M; Rizzo M; Johnson A; Bosch-Traberg H; Madsen J; Cariou B
    Diabetes Care; 2016 Sep; 39(9):1501-9. PubMed ID: 27311491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
    Raccah D; Miossec P; Esposito V; Niemoeller E; Cho M; Gerich J
    Diabetes Metab Res Rev; 2015 Feb; 31(2):204-11. PubMed ID: 25115916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
    Dailey GE; Dex TA; Roberts M; Liu M; Meneilly GS
    J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
    Meneilly GS; Roy-Duval C; Alawi H; Dailey G; Bellido D; Trescoli C; Manrique Hurtado H; Guo H; Pilorget V; Perfetti R; Simpson H;
    Diabetes Care; 2017 Apr; 40(4):485-493. PubMed ID: 28188240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.
    Onishi Y; Niemoeller E; Ikeda Y; Takagi H; Yabe D; Seino Y
    J Diabetes Investig; 2015 Mar; 6(2):201-9. PubMed ID: 25802728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
    Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M
    J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients.
    Chen X; Lv X; Yang G; Lu D; Piao C; Zhang X; Jiang H; Xie Y; Yang J; Li X; Li Y; Xiao X; Li Y; Sun L; Zheng S; Cheng Q; Peng Y; Yang W
    J Diabetes; 2017 Feb; 9(2):158-167. PubMed ID: 26989888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
    Bonadonna RC; Blonde L; Antsiferov M; Berria R; Gourdy P; Hatunic M; Mohan V; Horowitz M
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28303626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.
    Ahrén B; Vorokhobina N; Souhami E; Demil N; Ye J; Aronson R
    J Diabetes Complications; 2014; 28(5):735-41. PubMed ID: 25012990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
    Okere AN; Montesdeoca J; Glasper A; Diaby V
    Curr Diabetes Rev; 2018; 14(4):363-375. PubMed ID: 28738763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Wei ZG; Wang MC; Zhang HH; Wang ZY; Wang GN; Wei FX; Zhang YW; Xu XD; Zhang YC
    Medicine (Baltimore); 2018 Dec; 97(51):e13710. PubMed ID: 30572502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
    Tonneijck L; Muskiet MHA; Twisk JW; Kramer MHH; Danser AHJ; Joles JA; Smits MM; van Raalte DH
    Hypertension; 2018 Aug; 72(2):314-322. PubMed ID: 29915021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
    Seino Y; Terauchi Y; Wang X; Watanabe D; Niemoeller E;
    J Diabetes Investig; 2018 Jan; 9(1):108-118. PubMed ID: 28195447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.